公司資料
DiaMedica Therapeutics 股價、新聞與催化劑
- 股票代碼:
- DMAC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
6.52 USD (0.00%)
收盤價
最後更新: 2026年8月21日
311M USD
市值
股價為何變動
As of Aug 21, 2026, DMAC was little changed and closed at $6.52. No new same-company headline was identified in the current news window.
公司概覽
Recombinant Kallikrein Therapy
DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion.
Preeclampsia Program
Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies are intended to assess safety, pregnancy prolongation and dose selection for a potential multinational Phase 3 program.
Fetal Growth Restriction
An investigator-sponsored Phase 2 study evaluates whether DM199 can improve placental blood flow and fetal outcomes in pregnancies affected by fetal growth restriction.
Acute Ischemic Stroke
ReMEDy2 is a Phase 2/3 study of DM199 in acute ischemic stroke. The trial is progressing toward an interim analysis based on a prespecified enrollment threshold.
未來催化劑
- Topline results from the first Phase 2 fetal-growth-restriction cohort in September 2026.
- First patient dosing in the Canada Phase 2 early-onset preeclampsia study in the fourth quarter of 2026.
- Interim analysis from the Phase 2/3 ReMEDy2 acute-ischemic-stroke trial in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。